uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
5-alpha reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, UCR-Uppsala Clinical Research Center.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Endocrine Surgery.
2015 (English)In: Cancer Causes and Control, ISSN 0957-5243, E-ISSN 1573-7225, Vol. 26, no 9, 1289-1297 p.Article in journal (Refereed) Published
Abstract [en]

5-alpha reductase inhibitors (5-ARI) have been suggested to increase the risk of male breast cancer. The aim of this study was to study the risk of breast cancer in men on 5-ARI, in men with benign prostatic hyperplasia (BPH) not on 5-ARI, and in men without BPH. We performed a population-based cohort study in Sweden with data from The Prescribed Drug Register, The Patient Register, and The Cancer Register. Men on 5-ARI, men on alpha-blockers, or men who had undergone a transurethral resection of the prostate (TUR-P) prior to or during 2006-2008 were included as exposed to BPH and a specific treatment thereof. For each exposed man, five unexposed men were selected. Risk of breast cancer was calculated in Cox proportional hazard models. There were 124,183 exposed men and 545,293 unexposed men, and during follow-up (median 6 years), 99 men with breast cancer were diagnosed. Compared to unexposed men, men on 5-ARI had a hazard ratio (HR) of breast cancer of 0.74 (95 % confidence interval (CI) 0.27-2.03), men on alpha-blockers had HR 1.47 (95 % CI 0.73-2.95), and men with a TUR-P had HR 1.99 (95 % CI 1.05-3.75). No increased risk of breast cancer was observed for men on 5-ARI. However, the increased risk of breast cancer among men who had undergone a TUR-P, a strong indicator of BPH, suggests that the endocrine milieu conducive to BPH is associated with male breast cancer.

Place, publisher, year, edition, pages
2015. Vol. 26, no 9, 1289-1297 p.
Keyword [en]
5-alpha reductase inhibitors, Male breast cancer, Benign prostatic hyperplasia
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-262410DOI: 10.1007/s10552-015-0622-4ISI: 000359941800007PubMedID: 26109464OAI: oai:DiVA.org:uu-262410DiVA: diva2:855314
Swedish Cancer Society, 11 0471 11 0718Swedish Research Council, 2010-5950
Available from: 2015-09-21 Created: 2015-09-15 Last updated: 2015-11-05Bibliographically approved

Open Access in DiVA

fulltext(689 kB)16 downloads
File information
File name FULLTEXT01.pdfFile size 689 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Garmo, HansHolmberg, Lars
By organisation
UCR-Uppsala Clinical Research CenterEndocrine Surgery
In the same journal
Cancer Causes and Control
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 16 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 179 hits
ReferencesLink to record
Permanent link

Direct link